The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $4.0, along with a high estimate of $9.00 and a low estimate of $2.00. No alteration is ...

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at ...

The most common retinal disease among the aging population is age-related macular degeneration (AMD), accounting for approximately ... An early form of AMD, known as dry AMD, makes up approximately 90 ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to ...

For the past several years, the halls of the Las Vegas Convention Center have been lousy with AR/VR/XR smart glasses. While ...

SolidddVision smartglasses, which correct vision for people living with vision loss due to macular degeneration, will debut at CES.

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...